Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Dr. Reddy’s Laboratories Ltd ADR

Healthcare US RDY

13.255USD
0.01(0.11%)

Last update at 2026-06-05T20:00:00Z

Day Range

13.2313.37
LowHigh

52 Week Range

50.4173.17
LowHigh

Fundamentals

  • Previous Close 13.24
  • Market Cap11211.19M
  • Volume817104
  • P/E Ratio18.30
  • Dividend Yield0.72%
  • EBITDA77161.00M
  • Revenue TTM266854.01M
  • Revenue Per Share TTM268.17
  • Gross Profit TTM 113840.00M
  • Diluted EPS TTM3.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 60485.00M 32298.00M 28324.00M 18032.00M 22443.00M
Minority interest - - - - 0.00000M
Net income 45073.00M 23568.00M 19149.00M 19498.00M 18795.00M
Selling general administrative 46466.00M 62081.00M 54559.00M 50129.00M 707.00M
Selling and marketing expenses 59465.00M - - - -
Gross profit 202972.00M 113840.00M 103077.00M 94009.00M 83430.00M
Reconciled depreciation 12502.00M 11824.00M 12796.00M 12472.00M 12190.00M
Ebit 96282.00M 40818.00M 36062.00M 37055.00M 11416.00M
Ebitda 108784.00M 52642.00M 48858.00M 49527.00M 23606.00M
Depreciation and amortization 12502.00M 11824.00M 12796.00M 12472.00M 12190.00M
Non operating income net other - - - - 0.00000M
Operating income 96282.00M 40818.00M 36062.00M 37055.00M 20888.00M
Other operating expenses 160522.00M 177353.00M 156763.00M 141840.00M 132963.00M
Interest expense 1428.00M 958.00M 970.00M 983.00M 1163.00M
Tax provision 15412.00M 8730.00M 9175.00M -1466.00000M 3648.00M
Interest income 1058.00M 3077.00M 1653.00M 2034.00M 1555.00M
Net interest income -1428.00000M 2119.00M 1653.00M -90.00000M -119.00000M
Extraordinary items - 44.00M 313.00M 41.00M -3.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 15412.00M 8730.00M 9175.00M -1466.00000M 3648.00M
Total revenue 245879.00M 214391.00M 189722.00M 174600.00M 153851.00M
Total operating expenses 117615.00M 76802.00M 70118.00M 61249.00M 62542.00M
Cost of revenue 42907.00M 100551.00M 86645.00M 80591.00M 70421.00M
Total other income expense net -35797.00000M -8520.00000M -7738.00000M -19023.00000M 438.00M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 45073.00M 23568.00M 19149.00M 19498.00M 18795.00M
Net income applicable to common shares 45073.00M 23568.00M 19149.00M 19498.00M 18795.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 322851.00M 296654.00M 265491.00M 232241.00M 225427.00M
Intangible assets 30724.00M 27246.00M 35648.00M 27659.00M 44367.00M
Earning assets - - - - -
Other current assets 15120.00M 13902.00M 14509.00M 5755.00M 12536.00M
Total liab 89990.00M 106127.00M 90510.00M 77253.00M 85230.00M
Total stockholder equity 232861.00M 190527.00M 174981.00M 154988.00M 140197.00M
Deferred long term liab - - - - 0.00000M
Other current liab 48862.00M 41595.00M 33514.00M 39361.00M 27415.00M
Common stock 833.00M 832.00M 832.00M 831.00M 830.00M
Capital stock 833.00M 832.00M 832.00M 831.00M 830.00M
Retained earnings 215593.00M 175712.00M 157934.00M 144247.00M 128646.00M
Other liab - 2539.00M 2739.00M 3135.00M 3530.00M
Good will 5474.00M 4418.00M 4568.00M 3994.00M 3902.00M
Other assets 7124.00M 13729.00M 11582.00M 14795.00M 5227.00M
Cash 5779.00M 14852.00M 14829.00M 2053.00M 2228.00M
Cash and equivalents 2928.00M 75.00M 316.00M 118.00M 111.00M
Total current liabilities 85721.00M 97842.00M 81472.00M 72814.00M 59700.00M
Current deferred revenue 1981.00M 2576.00M 2033.00M 1910.00M 1351.00M
Net debt 7693.00M 18993.00M 15479.00M 20049.00M 36153.00M
Short term debt 12194.00M 28099.00M 24009.00M 20798.00M 16381.00M
Short long term debt 12194.00M 28099.00M 24009.00M 20315.00M 16324.00M
Short long term debt total 13472.00M 33845.00M 30308.00M 22102.00M 38381.00M
Other stockholder equity 15169.00M 12924.00M 14889.00M 9910.00M 10721.00M
Property plant equipment 66294.00M 62169.00M 57111.00M 52332.00M 54088.00M
Total current assets 204255.00M 181106.00M 148249.00M 130370.00M 114501.00M
Long term investments 6089.00M 7986.00M 8333.00M 3091.00M 3342.00M
Net tangible assets - 158863.00M 134765.00M 123335.00M 91928.00M
Short term investments 60969.00M 29513.00M 19744.00M 23687.00M 22529.00M
Net receivables 72485.00M 70049.00M 52386.00M 61754.00M 43269.00M
Long term debt 0.00000M 5746.00M 6299.00M 0.00000M 21448.00M
Inventory 48670.00M 50884.00M 45412.00M 35066.00M 33579.00M
Accounts payable 22684.00M 25572.00M 21916.00M 10745.00M 14553.00M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 1266.00M 1059.00M 1326.00M 2421.00M 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 832.00M 831.00M 830.00M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - -1967.00000M -1006.00000M -535.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 12715.00M 948.00M 952.00M 2581.00M 1059.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 118596.00M 115548.00M 117242.00M 101871.00M 110926.00M
Capital lease obligations 1278.00M 2963.00M 3363.00M 1787.00M 609.00M
Long term debt total 1278.00M 5746.00M 6299.00M 1304.00M 22000.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -41371.00000M -11201.00000M 4110.00M -4923.00000M -7727.00000M
Change to liabilities - 4412.00M 2861.00M 1576.00M 398.00M
Total cashflows from investing activities -41373.00000M -26387.00000M -22660.00000M -4923.00000M -7727.00000M
Net borrowings - 2735.00M 6094.00M -19165.00000M -15182.00000M
Total cash from financing activities -26861.00000M -2422.00000M -298.00000M -25159.00000M -21326.00000M
Change to operating activities - 4014.00M -3349.00000M 4821.00M 4122.00M
Net income 60485.00M 23568.00M 19149.00M 19498.00M 18795.00M
Change in cash -9073.00000M 32.00M 12858.00M -266.00000M -314.00000M
Begin period cash flow 14852.00M 14820.00M 1962.00M 2228.00M 2542.00M
End period cash flow 5779.00M 14852.00M 14820.00M 1962.00M 2228.00M
Total cash from operating activities 58873.00M 28108.00M 35703.00M 29841.00M 28704.00M
Issuance of capital stock 368.00M 334.00M 269.00M 4.00M 0.00000M
Depreciation 12502.00M 11824.00M 12796.00M 12472.00M 12190.00M
Other cashflows from investing activities -30050.00000M 873.00M 1220.00M 1016.00M 781.00M
Dividends paid 4979.00M 4146.00M 4147.00M 3916.00M 4002.00M
Change to inventory -2654.00000M -5328.00000M -9881.00000M -1487.00000M -8496.00000M
Change to account receivables - -17012.00000M 2081.00M -12446.00000M 6.00M
Sale purchase of stock 368.00M 334.00M -1193.00000M -474.00000M -535.00000M
Other cashflows from financing activities -21235.00000M 2175.00M 9270.00M 2627.00M -16789.00000M
Change to netincome - 6630.00M 12046.00M 5407.00M -4118.00000M
Capital expenditures 18864.00M 19049.00M 12561.00M 6115.00M 7491.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -7855.00000M -13914.00000M -8288.00000M -7536.00000M -5771.00000M
Stock based compensation 397.00M 592.00M 584.00M 521.00M 389.00M
Other non cash items -21956.00000M -2692.00000M 2287.00M 6352.00M -547.00000M
Free cash flow 40009.00M 9059.00M 23142.00M 23726.00M 21213.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RDY
Dr. Reddy’s Laboratories Ltd ADR		 0.01 0.11% 13.26 18.30 18.32 0.04 3.63 0.04 0.13
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy’s Laboratories Ltd ADR

8-2-337, Road No. 3, Hyderabad, India, 500034

Key Executives

Name Title Year Born
Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council 1960
Mr. Kallam Satish Reddy B.Tech., M.S. Chairman & Member of the Management Council 1967
Mr. Erez Israeli M.B.A. CEO & Member of the Management Council 1968
Mr. Parag Agarwal CFO & Member of Management Council 1966
Mr. Deepak Sapra M.B.A. CEO of API & Services & Member of Management Council 1975
Mr. Venkata Ramana Motupalli M.B.A., MBA CEO of Branded Markets - India & Emerging Countries and Member of Management Council 1969
Ms. Archana Bhaskar B.Sc., M.B.A. EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council 1967
Mr. Sanjay Sharma B.Tech. Exec. VP, Global Head of Global Manufacturing & Member of Management Council 1968
Mr. Marc Kikuchi B.A., M.B.A. CEO of North America Generics & Member of Management Council 1969
Mr. Patrick Aghanian B.A., M.B.A. CEO of European Generics & Member of Management Council 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.